This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cytokinetics' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Cytokinetics, Inc. (CYTK)

Q2 2012 Earnings Call

July 31, 2012, 4:30 p.m. ET

Executives

Sharon Barbari - EVP, Finance & CFO

Robert Blum - President & CEO

Andrew Wolff - SVP, Clinical Research and Development, & CMO

Fady I. Malik – SVP Research and Early Development

Analysts

Ritu Baral – Canaccord Genuity

Charles Duncan - JMP Securities

Michael King – Rodman & Renshaw LLC

Simos Simeonidis – Cowen and Company

Chad Messer – Needham & Co.

George Zavoico – Mcnicoll, Lewis & Vlak

Presentation

Operator

Good afternoon, and welcome Ladies and Gentlemen to the Cytokinets second quarter 2012 conference call. (Operator Instructions)

I will now turn the call over to Sharon Barbari, Cytokinets Executive Vice President of Finance and CFO. Please go ahead.

Sharon Barbari

Good afternoon, and thank you for joining the Cytokinets senior management team on this conference call today. Also present during this call are Robert Blum, our President and Chief Executive Officer, Dr. Andrew Wolff, Senior Vice President of Clinical Research and Development and Chief Medical Officer, and Dr. Fady Malik, Senior Vice President of Research and Early Development.

Following the forward-looking statement disclaimer, Robert will provide a summary overview of the past quarter along with brief highlights on the advancement of clinical development pipeline including omecamtiv mecarbil and tirasemtiv, formerly referred to as CK2017357.

Andy will then provide details of recent progress in our skeletal muscle activator program directed to the potential treatment of ALS. And Fadi will provide details on recent progress in our cardiac muscle activator program directed to the potential treatment of heart failure.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs